Summary. The effects of two different protein synthesis inhibitors (cycloheximide and puromycin) on the ovulatory process were examined in vitro using a perfused rat ovary model. Ovaries of PMSG (20i.u.)-primed rats were perfused for 21 h. Release of cyclic adenosine 3\m='\,5\m='\-monophosphate(cAMP) and steroids (progesterone, testosterone, and oestradiol) was measured and the number of ovulations was estimated by counting released oocytes. Unstimulated control ovaries did not ovulate whereas addition of LH (0\m=.\1\g=m\g/ml)plus 3-isobutyl-1-methylxanthine (IBMX; 0\m=.\2 mm) resulted in 16\m=.\7\ m=+-\3\ m=. \ 5 ovulations per treated ovary. Cycloheximide (5 \g=m\g/ml)totally inhibited the ovulatory effect of LH + IBMX when present from the beginning of the perfusions and also when added 8 h after LH + IBMX. No inhibition was seen when cycloheximide was added 10 h after LH + IBMX (1\ p=n-\ 1\ m=. \ 5 h before the first ovulation; 15\m=.\2\m=+-\4\m=.\4ovulations per treated ovary). Puromycin (200 \g=m\g/ml)completely blocked ovulation when present from the beginning of the perfusions and the inhibition was \m=simeq\60% (6\m=.\5 \m=+-\2\m=.\2ovula-tions per treated ovary) when the compound was added 8 h after LH + IBMX. Both inhibitors increased LH + IBMX-stimulated cAMP release substantially, but decreased the release of progesterone, testosterone and oestradiol. These results indicate that de-novo protein synthesis is important late in the ovulatory process for follicular rupture to occur.
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Introduction
The preovulatory surge of luteinizing hormone (LH) initiates a series of biochemical events leading to oocyte maturation, follicular rupture, and luteinization of the follicle (LeMaire et ai, 1979) .
Shortly after the LH surge there is an increase in ovarian protein synthesis (Wang & Greenwald, 1985) which is essential for the stimulation of steroidogenesis (Lieberman et ai, 1975; Greenwald & Limback, 1984) and oocyte maturation (Tsafriri et ai, 1973) . This change in protein synthesis may also be important for ovulation, since inhibitors of protein synthesis administered in vivo can inhi¬ bit ovulation in the rabbit (Pool & Lipner, 1966; Espey, 1986) , the hamster (Alleva et ai, 1979; Wang & Greenwald, 1985) and the rat (Espey et ai, 1985) . However, in these studies discrepancies were noted regarding the optimum time of administration. Furthermore, protein synthesis inhibi¬ tors are known to induce toxic syndromes (Young et ai, 1963) and such conditions may influence the ovulatory process in vivo. To avoid such gross effects of protein synthesis inhibitors, we have examined the action of two chemically different inhibitors of protein synthesis on ovulation in a well-characterized in-vitro perfusion system (Janson et ai, 1982) which has been used to perfuse rat ovaries (Koos et ai, 1984a; Brännström et ai, 1987a) . In parallel, the production of cyclic AMP and steroids was monitored to define the influence of inhibition of protein synthesis on these steps in the ovulatory process. (Koos et ai, 1984a Perfusion procedure. The perfusion apparatus and procedure have been described in detail elsewhere (Janson el ai, 1982; Brännström et ai, 1987a Ovaries were perfused for 1 h before LH (0-1 µg/ml) and IBMX (0-2 mM) were added. Cycloheximide (5 µg/ml) or puromycin (200 µg/ml) were present in the medium from the start of the perfusions. At 2 h after addition of LH + IBMX, the ovaries were transferred to other perfusion systems containing medium identical to that in the first perfusions plus L-[14C]leucine (0-3 µ / ) and perfused for an additional 1 h. The ovaries were homogenized in 1-5 ml 5% trichloroacetic acid (TCA) and centrifuged at 1000g for 10 min. The pellets were dissolved in 3 ml 5% TCA with 1% unlabelled L-leucine and heated at 85°C for 15 min, followed by centrifugation at 1000 g for 10 min. The pellets were washed in 3 ml ethanol-chloroform-diethylether (3:2:1; by vol.) followed by centrifugation for 10min at 1000 g, a procedure which was repeated three times. Finally, the precipitates were washed in 2 ml diethyl ether, dried and dissolved in 1 ml 1 M-NaOH. Protein concentration was measured by the method of Lowry et ai (1951) . Finally, 100 µ of this solution were mixed with 3 ml Opti Safe scintillation fluid (LKB, Loughborough, UK) and counted. Incorporation was expressed as c.p.m./mg protein.
Steroid and cAMP assays. Progesterone, testosterone and oestradiol concentrations were measured by radioim¬ munoassays (Hillensjö et ai, 1976; Hedin et ai, 1983 ) using specific antisera obtained from Immuno-Chemieals, Tumba, Sweden. The cross-reactivities ofthe specific antisera with other steroids were as follows: progesterone, 6-7% with 17a-hydroxyprogesterone, 0-4% with pregnenolone, 01% with testosterone, and < 0-001% with oestradiol; oestradiol, 0-2% with oestriol, and <0T% with progesterone and testosterone; testosterone, 4% with androstene¬ dione, 0-1% with oestradiol, and < 0-001% with progesterone. Intra-assay and inter-assay coefficients of variation in the progesterone, testosterone and oestradiol assays were 11% and 15%, 10% and 10%, 10% and 9%, respectively, and the sensitivities were 4 pg progesterone, 5 pg testosterone and 4 pg oestradiol.
Cyclic AMP levels in the medium were determined by a protein binding assay (Gilman, 1970) with minor modifi¬ cations (Holmes et ai, 1986) . The sensitivity ofthe assay was 0-5 pmol and the intra-assay coefficient of variation was 15%.
Vital staining ofoocytes. A stock solution of 5 mg fluorescein-diacetate/mi (FDA; Sigma) in acetone was prepared. The solution was diluted 104 times in Eagles MEM with Earle's salts (Gibco, Paisley, UK) immediately before stain¬ ing. Oocyte-cumulus complexes were mechanically isolated from follicles of perfused ovaries and incubated for 5 min in FDA followed by washing in 1 ml plain medium for 5 min. Cells that have esterase will hydrolyse the hydrophobic FDA molecule to a more hydrophilic fluorescein molecule, which will be trapped within the cell if the cell membrane remains intact (Rotman & Papermaster, 1966 (Table 2) . Cycloheximide (5 µg/ml) totally blocked LH + IBMX-stimulated ovulation in 5 of 6 ovaries, when present from the beginning of the perfusions (Group III) and in all 6 ovaries when added 8 h after LH + IBMX (Group IV). When cycloheximide was added 10 h after LH + IBMX (Group V), no significant (P > 005) inhibition of ovulation was seen, when compared to Group II. Puromycin (200µg/ml) completely inhibited LH + IBMX-stimulated ovulation, when present in the medium from the beginning of the perfusions (Group VI), but only partly (6-5 ± 2-2 ovulations per treated ovary) when added at 8 h after LH + IBMX (Group VII). (Gokal et ai, 1986) . Puromycin acts by competing with aminoacyl-transfer RNA for the site on the 50S subunit of the ribosome, causing premature amino acid chain termination (Pestka, 1971) . The present study and earlier studies (Ahrén et ai, 1968; Tsafriri et ai, 1973) showed that cycloheximide and puromycin in the concentrations used here are effectively inhibiting ovarian protein synthesis in vitro.
The results of the present study clearly demonstrate that both these compounds can inhibit ovulation in the isolated perfused rat ovary. Earlier experiments with in-vivo administration of protein synthesis inhibitors have shown that these substances are most effective when administered before or soon after the ovulatory hCG injection and ineffective if added late in the preovulatory period (Pool & Lipner, 1966; Alleva et ai, 1979; Espey et ai, 1985; Espey, 1986) . The inhibition of ovulation in these in-vivo studies is probably due to inhibition of protein synthesis late during the follicular development or early in the ovulatory process. However, the present study shows that cycloheximide is able to suppress ovulation almost totally even when added to the perfusion system as late as 8 h after treatment with LH + IBMX. When added at 10 h (1-2 h before the first expected ovulation) no inhibition is seen. Puromycin also inhibits ovulation completely when present from the beginning of the perfusions and is partly effective when added 8 h after LH + IBMX. The difference in results between in-vivo and in-vitro experiments is at present unclear and may be explained by differences in dosages used or discrepancies in time between drug administration and effect on the ovary. Both inhibitors of protein synthesis increase the cyclic AMP release into the perfusion medium and decrease the steroid release. No signs of devitalization ofthe tissue are seen, as indicated by normal vital staining of oocyte-cumulus complexes after perfusion for 21 h and a continued release of cAMP and steroids into the medium.
The induction of cAMP production appears to be a crucial early step in the ovulatory process. Holmes et ai (1986) were able to induce ovulations in the isolated perfused rabbit ovary by forsko¬ lin, a non-specific activator of adenylate cyclase. Brännström et al. (1987b) could induce ovulations in perfused rat ovaries by adding dibutyryl cAMP and the phosphodiesterase inhibitor IBMX to the medium. In the present study, addition of protein synthesis inhibitors increases cAMP release. A clear conclusion from our data is therefore, that the protein synthesis inhibitors block ovulation by a mechanism of action beyond adenylate cyclase. The increase of cAMP confirms earlier observations using other experimental preparations such as incubated rat follicles (Lamprecht et ai, 1977) and prepubertal rat ovaries (Bergh & Ahrén, 1980) . The increased release of cAMP into the medium is most likely due to an increased production of the nucleotide rather than an inhibi¬ tion ofthe activity ofthe cAMP-degrading phosphodiesterase enzyme, as indicated by a persistence ofthe effect in the presence of IBMX (Bergh & Ahrén, 1980) and failure of cycloheximide treatment to produce any significant change in phosphodiesterase activity in thyroid cells (Rapoport & Adams, 1976) . The increased synthesis of cAMP could be explained by an inhibition of synthesis of inhibitory proteins which normally reduce adenylate cyclase activity at gonadotrophin-induced desensitization (Hedin & Ahrén, 1983) . The results in the present study showing no effect of cyclo¬ heximide by itself on cAMP release confirm findings on incubated prepubertal rat ovaries (K. Ahrén & C. Bergh, unpublished data) and show that the stimulation of cAMP release by the protein synthesis inhibitor is only evident upon LH stimulation.
In the present study, 75-85% ofthe ovulated oocytes were immature when examined at the end of the perfusions. This finding is in line with earlier results from in-vitro incubated rat follicles (Lindner et ai, 1974; Hillensjö et ai, 1978) , in which addition of phosphodiesterase inhibitors together with LH arrested the normal LH-induced stimulation of meiosis. The arrested meiosis is probably due to a prolonged increase in intracellular cAMP levels in the oocyte-cumulus complex (Cho et ai, 1974) . This is further supported by our earlier findings (unpublished) that more than 90% of the ovulated oocytes from ovaries stimulated with LH + IBMX mature spontaneously if transferred to control medium and incubated for 4 h. An early step in the chain of preovulatory events is the LH-induced increase in follicular steroid production. The importance of this increase in steroidogenesis for follicular rupture is a matter of controversy. In contrast to reports from experiments in vivo on the rat (Snyder et ai, 1984) and the sheep (Murdoch et ai, 1986) indicating an important role for progesterone, Holmes et ai (1985) were unable to affect the ovulation rate in perfused rabbit ovaries by treatment with an inhibitor of 3ß-hydroxysteroid dehydrogenase, which converts pregnenolone to progesterone. However, our data (Brännström & Janson, 1988) for the perfused rat ovary seem to indicate that high progester¬ one levels are of importance for ovulation in the rat, and species differences might therefore exist. Androgens (Mori et ai, 1977) , in contrast to oestrogens (Lipner & Wendelken, 1971; Koos et ai, 1984b) , have also been suggested to play a role in the ovulatory process. In the present study, inhibition of protein synthesis resulted in a decreased release of the three steroids measured. A shortage of steroid precursors has been suggested to explain the cycloheximide-induced inhibition of steroidogenesis in the hamster (Greenwald & Limback, 1984) . In rat luteal tissue, a cycloheximide-inhibitable process forming the key step in regulating the availability of mitochondrial choles¬ terol to the side-chain cleavage system has been described (Toaffeí ai, 1979) . The various steps in steroidogenesis beyond 3ß-hydroxysteroid dehydrogenase have been reported to be unaffected in cycloheximide-treated granulosa cells (Greenwald & Limback, 1984) . In the present study, cyclo¬ heximide inhibited ovulation when added at 8 h after LH + IBMX, a time well after the shut down of testosterone and oestradiol release but with a continued output of progesterone. A possible mechanism of action for the ovulation-blocking properties of protein synthesis inhibitors could, therefore, be specific interference with progesterone production.
Prostaglandins are considered to play a key role in the ovulatory process (for review, see Arm¬ strong, 1981). The increase in prostaglandin concentrations in the rat ovary occurs after a lag phase of 2-4 h after LH stimulation and maximal levels are seen around the time of ovulation (Bauminger et ai, 1978) . Inhibition of protein synthesis may interfere with arachidonic acid release (Pong et ai, 1977) or with later steps in prostaglandin biosynthesis. High levels of prostaglandin endoperoxidase synthase, a key enzyme in the cyclo-oxygenase pathway of arachidonic acid metabolism, are detected in granulosa cells of preovulatory follicles 7 h after hCG injection in vivo (Hedin et ai, 1987) or 7 h after addition of LH + IBMX to the in-vitro perfused rat ovary (Hedin et ai, 1988) . The induction of enzymes in the prostaglandin pathway of arachidonic acid metabolism has therefore probably taken place before 8 h, when addition of cycloheximide was still effective. It is therefore unlikely that the mechanism behind the late effects of protein synthesis inhibitors involves an interference with the induction of prostaglandin-synthesizing enzymes. However, it cannot be ruled out that the protein synthesis inhibitors lower prostaglandin synthesis by decreasing the availability of arachidonic acid (Pong et ai, 1977) .
Plasminogen activator levels within the ovary rise before ovulation and plasminogen activator has been suggested to be a mediator in the ovulatory process (Beers et ai, 1975) . Plasminogen activator converts plasminogen to plasmin, which in turn may activate latent collagenase to de¬ grade collagen and thereby causing a weakening of the follicular wall (Reich et ai, 1985) . A late preovulatory activation of collagenase in the ovary has been verified (Curry et ai, 1985) and inhibi¬ tors of collagenase are able to inhibit ovulation in the perfused rat ovary (Brännström et ai, 1988) . The most likely interpretation of our results is therefore that the late inhibition of ovulation seen with cycloheximide is due to inhibition of plasminogen activator production and collagenase activation.
In conclusion, the results from the present study show that inhibition of ovarian protein synthesis can block ovulation by affecting metabolic steps beyond cAMP, where an interference with production of progesterone or prostaglandins is possible but an interference with plasminogen activator and/or collagenase seems more likely.
